Merck & Co reported stronger-than-expected quarterly earnings thanks to rising Keytruda sales. However, Gardasil's weak ...

The company’s MI Cancer Seek is approved as a companion diagnostic for multiple cancer therapies, including MSD’s Keytruda, ...

The third-quarter earnings season was at its peak this week for large drugmakers, with several companies — Eli Lilly LLY, ...

Merck MRK reported third-quarter 2024 adjusted earnings of $1.57 per share, which beat the Zacks Consensus Estimate of $1.50. Earnings declined 26% year over year on a reported basis and 23% excluding ...

A partial clinical hold was placed on the registrational trial after results showed variance between squamous and ...

Merck's overall sales in China dropped, although Keytruda, their cancer treatment, performed robustly. This image is AI-generated and does not depict any real-life event or location. It is a fictional ...

“When the radiologist reads the images, they’re looking for any changes ... Carboplatin, paclitaxel and pembrolizumab (Keytruda) became my partners in crime for three months, working ...

Image credit: Shutterstock/Andrii Yalanskyi ... The therapy is being tested alone and in combination with MSD’s blockbuster cancer treatment Keytruda (pembrolizumab). Earlier this year, RAPT shared ...

Keytruda in early-stage triple-negative breast cancer led to immune-related adverse effects, including severe GI issues and ...

Analysts say the drug could emerge as a potential competitor to Merck’s blockbuster immunotherapy Keytruda. Keytruda is ...